Larimar Therapeutics Inc

Flynn James E. buys 4M shares of Larimar Therapeutics at $5—an insider confidence boost amid strong gains, yet concentration may spark future sell‑off risk.

Insider buying at Larimar Therapeutics signals confidence in its rare‑disease pipeline, market‑access strategy and financial strength—an optimistic outlook for investors.

Insider buying at Larimar Therapeutics signals management confidence amid market volatility – learn why executives are staking on LAR‑001’s breakthrough potential.